目的:提供一项初步研究的报告,以评估RayOne增强单视(EMV)的视力(VA)和对比敏感度,一种独特的非衍射增强单焦点人工晶状体(IOL),以增加焦点范围。
方法:对25例(50只眼)白内障手术后双侧植入EMVIOL的患者进行回顾性病例系列研究。收集的数据包括生物测定,球形当量(SE),和VA在附近,中间,和距离。患者在第1天复查,1周,术后1个月。在1个月时检查对比敏感度(CS)。
结果:该研究包括14名男性(56%)。参与者年龄为61.4±7.4岁。单眼未校正的近距离和远距离VA在1个月时的最小分辨率角(logMAR)从0.33±0.13提高到0.05±0.07,从0.63±0.31提高到0.05±0.10log(两者均P<0.001)。双眼未矫正的近距离和远距离VA从0.09±0.18和0.14±0.27提高到0.05±0.06和0.00±0.09logMAR,分别(P<0.001)。SE从-0.23±2.55变为-0.33±0.46。3个月时的CS为1.74±0.21。在1个月,48只眼(96%)达到未校正的中间VA6/15(0.4logMAR)或更好。当比较未矫正中间视力≥0.2(6/9或更好)的眼睛与1个月时logMAR<0.2的眼睛时,组间基线参数无差异.
结论:初步研究表明,非衍射型EMVIOL是安全的,有效,稳定,提供良好的距离和中间视力和良好的近视力。
OBJECTIVE: To provide the reports of a pilot study to assess the visual acuity (VA) and contrast sensitivity with RayOne enhanced monovision (EMV), a unique nondiffractive enhanced monofocal intraocular lens (IOL) to increase the range of focus.
METHODS: A retrospective case series study was conducted by analyzing 25 patients (50 eyes) who had bilateral implantation of EMV IOL after cataract surgery. Data collected included biometry, spherical equivalent (SE), and VA for near, intermediate, and distance. Patients were reviewed at 1 day, 1 week, and 1 month after surgery. Contrast sensitivity (CS) was checked at 1 month.
RESULTS: The study included 14 males (56%). Age of participants was 61.4 ± 7.4 years. Uniocular uncorrected near and distance VA improved from 0.33 ± 0.13 to 0.05 ± 0.07 and from 0.63 ± 0.31 to 0.05 ± 0.10 log of minimum angle of resolution (logMAR) at 1 month (P < 0.001 for both). Binocular uncorrected near and distance VA improved from 0.09 ± 0.18 and 0.14 ± 0.27 to 0.05 ± 0.06 and 0.00 ± 0.09 logMAR, respectively (P < 0.001). SE changed from - 0.23 ± 2.55 to - 0.33 ± 0.46. CS at 3 months was 1.74 ± 0.21. At 1 month, 48 eyes (96%) achieved uncorrected intermediate VA 6/15 (0.4 logMAR) or better. When comparing eyes that had uncorrected intermediate vision of ≥ 0.2 (6/9 or better) to eyes that had < 0.2 logMAR at 1 month, there was no difference between groups with respect to baseline parameters.
CONCLUSIONS: The pilot study shows that the nondiffractive EMV IOL is safe, effective, and stable, providing excellent distance and intermediate vision and good near vision.